Wedbush Weighs in on Sangamo Therapeutics Inc’s FY2022 Earnings (SGMO)

Sangamo Therapeutics Inc (NASDAQ:SGMO) – Wedbush issued their FY2022 EPS estimates for shares of Sangamo Therapeutics in a research note issued on Monday. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will earn ($1.21) per share for the year. Wedbush has a “Neutral” rating and a $6.00 price objective on the stock.

A number of other research firms also recently weighed in on SGMO. BidaskClub downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Barclays started coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 target price on the stock. Zacks Investment Research downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Finally, Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $18.83.

Sangamo Therapeutics (SGMO) remained flat at $$20.55 during mid-day trading on Tuesday. The company had a trading volume of 1,632,011 shares, compared to its average volume of 1,694,764. Sangamo Therapeutics has a 52-week low of $3.65 and a 52-week high of $22.85. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1,780.00, a PE ratio of -29.78 and a beta of 2.87.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. During the same quarter in the prior year, the business earned ($0.27) EPS. The business’s revenue for the quarter was up 333.0% on a year-over-year basis.

In related news, Director Steven J. Mento sold 11,520 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $237,196.80. Following the sale, the director now owns 5,000 shares in the company, valued at approximately $102,950. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the sale, the director now owns 5,000 shares in the company, valued at approximately $73,350. The disclosure for this sale can be found here. Insiders sold a total of 89,953 shares of company stock worth $1,618,193 in the last 90 days. 5.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its position in Sangamo Therapeutics by 6.8% in the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 832 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Sangamo Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock valued at $2,353,000 after acquiring an additional 1,558 shares in the last quarter. Voya Investment Management LLC lifted its position in Sangamo Therapeutics by 10.7% in the 2nd quarter. Voya Investment Management LLC now owns 33,809 shares of the biopharmaceutical company’s stock valued at $298,000 after acquiring an additional 3,270 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in Sangamo Therapeutics by 29.3% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 4,300 shares in the last quarter. Finally, Nationwide Fund Advisors lifted its position in Sangamo Therapeutics by 13.5% in the 3rd quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 5,337 shares in the last quarter. 64.22% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/wedbush-weighs-in-on-sangamo-therapeutics-incs-fy2022-earnings-sgmo.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply